全文获取类型
收费全文 | 4337篇 |
免费 | 890篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 91篇 |
儿科学 | 142篇 |
妇产科学 | 73篇 |
基础医学 | 233篇 |
口腔科学 | 51篇 |
临床医学 | 1214篇 |
内科学 | 1136篇 |
皮肤病学 | 137篇 |
神经病学 | 328篇 |
特种医学 | 176篇 |
外科学 | 707篇 |
综合类 | 41篇 |
预防医学 | 248篇 |
眼科学 | 105篇 |
药学 | 135篇 |
中国医学 | 2篇 |
肿瘤学 | 425篇 |
出版年
2024年 | 18篇 |
2023年 | 144篇 |
2022年 | 50篇 |
2021年 | 145篇 |
2020年 | 209篇 |
2019年 | 84篇 |
2018年 | 234篇 |
2017年 | 173篇 |
2016年 | 213篇 |
2015年 | 183篇 |
2014年 | 282篇 |
2013年 | 359篇 |
2012年 | 162篇 |
2011年 | 145篇 |
2010年 | 248篇 |
2009年 | 293篇 |
2008年 | 171篇 |
2007年 | 149篇 |
2006年 | 172篇 |
2005年 | 146篇 |
2004年 | 92篇 |
2003年 | 93篇 |
2002年 | 94篇 |
2001年 | 105篇 |
2000年 | 78篇 |
1999年 | 78篇 |
1998年 | 59篇 |
1997年 | 75篇 |
1996年 | 65篇 |
1995年 | 60篇 |
1994年 | 36篇 |
1993年 | 26篇 |
1992年 | 67篇 |
1991年 | 65篇 |
1990年 | 50篇 |
1989年 | 44篇 |
1988年 | 42篇 |
1987年 | 26篇 |
1986年 | 36篇 |
1985年 | 56篇 |
1984年 | 37篇 |
1983年 | 32篇 |
1979年 | 21篇 |
1977年 | 17篇 |
1976年 | 19篇 |
1975年 | 21篇 |
1973年 | 18篇 |
1972年 | 16篇 |
1971年 | 16篇 |
1969年 | 20篇 |
排序方式: 共有5244条查询结果,搜索用时 15 毫秒
1.
Jamaal L. Benjamin MD PhD Rebecca Dennis DO Stacy White Jr MD David Munson MD Sudha A. Anupindi MD Maciej Piskunowicz MD Kassa Darge MD PhD Ami Gokli MD Misun Hwang MD 《Journal of ultrasound in medicine》2020,39(5):1031-1036
Bowel diseases of prematurity, including necrotizing enterocolitis, are dreaded ailments of neonates. Early diagnosis is difficult, with clinical and radiographic findings often inconclusive. We present a novel use of contrast-enhanced ultrasound in detection of pediatric bowel disease. Early identification of compromised blood flow or an at-risk bowel can be quantitatively detected and monitored. This ability has implications for guidance of emerging therapies, allowing targeting of inflammation. These findings represent an advancement in detection of bowel disease in neonates. 相似文献
2.
3.
4.
5.
6.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255
7.
Fibromyalgia is a syndrome of widespread pain, nonrestorative sleep, disturbed mood, and fatigue. Optimal treatment involves
a multidisciplinary approach with a team of health care providers using pharmacologic and nonpharmacologic treatment. Because
of the heterogeneity of the illness, management should be individualized for the patient. Pharmacologic treatment should address
issues of pain control, sleep disturbance, fatigue, and any underlying coexisting mood disorder. Nonpharmacologic treatment
should include patient education, a regular exercise and stretching program, and cognitive behavioral therapy. All of these
are essential to improving functional capacity and quality of life. This review provides general guidelines in initiating
a successful pharmacologic treatment program for patients with fibromyalgia. 相似文献
8.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
9.
10.